Pasireotide

Pasireotide (SOM230) is a synthetic cyclohexapeptide somatostatin analog and the first medical therapy approved by the United States Food and Drug Administration for the treatment of Cushing's disease, subsequently extended to acromegaly in a long-acting release formulation. Structurally distinct from the linear and octapeptide first-generation somatostatin analogs octreotide and lanreotide, pasireotide incorporates key pharmacophoric elements of native somatostatin-14 into a metabolically stable cyclohexapeptide scaffold containing unnatural amino acids, conferring broad binding across four of the five human somatostatin receptor subtypes (sst1, sst2, sst3, and sst5) with a binding affinity profile that is 30-fold higher at sst1, 5-fold higher at sst3, and 40-fold higher at sst5 compared to octreotide, while retaining comparable affinity at sst2 [1, 2]. The preferential sst5 agonism is the principal pharmacological differentiator: corticotroph adenoma cells in Cushing's disease express sst5 at substantially higher density than sst2, and the sst5-mediated suppression of adrenocorticotropic hormone (ACTH) secretion is the molecular basis for the efficacy of pasireotide in this indication where first-generation sst2-preferring analogs are ineffective [3, 4]. In a 12-month Phase 3 study of 162 patients with Cushing's disease (Colao et al. 2012, New England Journal of Medicine), subcutaneous pasireotide at 600 or 900 micrograms twice daily produced a median reduction in urinary free cortisol of approximately 50 percent by month 2 with normalization of urinary free cortisol in 15 to 26 percent of patients at month 6 [5]. In acromegaly, the Phase 3 PAOLA study (Gadelha et al. 2014, Lancet Diabetes and Endocrinology) demonstrated superior biochemical control with pasireotide long-acting release (LAR) at 40 and 60 mg monthly versus continued first-generation somatostatin analog therapy in patients inadequately controlled on octreotide or lanreotide, with 15 to 20 percent of pasireotide-treated patients achieving both growth hormone below 2.5 micrograms per liter and normalized insulin-like growth factor 1 versus zero percent in the active control group [6]. Pharmacokinetics after subcutaneous administration are characterized by rapid absorption (time to peak approximately 0.25 to 1 hour), a terminal elimination half-life of approximately 12 hours, hepatic clearance predominantly through biliary excretion, and dose-proportional exposure across the clinical dose range [7, 8]. The principal safety liability is hyperglycemia, observed in 73 percent of Cushing's disease patients in the Phase 3 study, mechanistically attributable to sst5-mediated suppression of insulin secretion and reduction of incretin hormones (glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide) from enteroendocrine cells, a predictable on-target effect that is manageable with antidiabetic agents and reversible upon discontinuation [9, 10]. Other adverse events include gastrointestinal symptoms (diarrhea, nausea, abdominal pain), cholelithiasis, hepatic transaminase elevations, QT interval prolongation on electrocardiogram, and bradycardia, a profile broadly consistent with the somatostatin analog class [11]. This monograph reviews the chemistry, synthesis, and structural pharmacology of pasireotide; the multi-receptor mechanism in molecular detail; the comprehensive human pharmacokinetic record; the preclinical pharmacology across pituitary, neuroendocrine, and oncologic models; the clinical evidence base across Cushing's disease, acromegaly, and neuroendocrine tumor indications; reconstitution, sourcing, and handling considerations; stack-interaction implications; adverse-event signal; and a comparative assessment of five somatostatin receptor agonist candidates against pasireotide on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).